ホーム / ニュース / Kelley Kendle, President of Certara’s Synchrogenix Division, Named to DBT ‘Top 40 Under 40’

Kelley Kendle, President of Certara’s Synchrogenix Division, Named to DBT ‘Top 40 Under 40’

List celebrates business achievers and innovators under the age of 40

PRINCETON, NJ – Oct. 6, 2016 – Certara®, the leading provider of decision support technology and consulting services for optimizing drug development and improving health outcomes, today announced that Kelley Kendle, president of Synchrogenix, its medical and regulatory writing consultancy, has been named a Delaware Business Times (DBT) 40 honoree. This is an annual listing of Delaware’s influential achievers and innovators under the age of 40.

“We are delighted to see Kelley receive this honor,” said Certara CEO Edmundo Muniz, MD, PhD. “Kelley has done a marvelous job transitioning Synchrogenix from an excellent regulatory writing and communications organization into the strategic, technology-enabled biopharmaceutical consulting powerhouse that it is today. She is a smart businesswoman, a born leader, and a constant inspiration to her team.”

The demand for Synchrogenix’s services is growing dramatically worldwide as sponsors recognize the hidden value that expert writing guidance can provide across the entire drug R&D and commercialization continuum.

Synchrogenix employs more than 200 medical and regulatory writing experts worldwide to bring a holistic approach to document development from data through to life-cycle management. Synchrogenix has mastered how to efficiently and accurately generate all the documents required for submission to global regulatory agencies and scientific forums, addressing various audiences across the life sciences. In addition to its expert team, Synchrogenix’s revolutionary artificial intelligence technology platform uses natural language processing to create initial drafts of regulatory documents and anonymize confidential information in response to the European Medicines Agency Policy 43 and Policy 70.

“I am very proud to receive this recognition on behalf of my wonderful team at Synchrogenix,” said Ms. Kendle. “I consider hiring and nurturing the best people as a key to success. Setting up the systems and processes for them to have the autonomy to be successful and to grow is my top priority. As president of a growing, multi-national company, my confidence comes in having faith in the systems so that we can scale with the same focus, quality and experience that we have been providing over the last 30 years.”

Certara(サターラ) について

Certara is a leading decision support technology and consulting organization committed to optimizing drug development and improving health outcomes. Certara’s solutions, which span drug discovery through patient care, use the most scientifically-advanced modeling and simulation technologies and regulatory strategies to increase the probability of regulatory and commercial success. Its clients include hundreds of global biopharmaceutical companies, leading academic institutions, and key regulatory agencies.

お問合せ先
Ellen Leinfuss, 609-216-9586
Chief Marketing Officer

※英語または日本語でお問合せください
Lisa Osborne, 206-992-5245
Rana Healthcare Solutions
lisa@ranahealth.com

※英語または日本語でお問合せください

Jieun W. Choe, Chief Strategy and Marketing Officer. jieun.choe@certara.com
トップに戻る
Powered by Translations.com GlobalLink OneLink Software